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Abstract. Painful bone metastases are common in prostate 
cancer, with current treatments including non-steroidal 
analgesics and opiates, surgery, external beam radiotherapy 
and bone-targeting β-emitting radiopharmaceuticals. The 
α-emitting isotope 223Ra-dichloride (Ra-223) has been 
associated with improved overall survival and increased 
time to first skeletal‑related events in patients with castra-
tion-resistant prostate cancer (CRPC) presenting with 
symptomatic bone metastases. The current study reports the 
case of a 70-year-old male patient, who was diagnosed with 
prostate cancer in 1999 upon presentation with increased 
prostate-specific antigen (PSA) levels and painful bone 
metastases in the context of CRPC. In November 2010, 
subsequent to undergoing hormonal blockage, the patient 
was treated with ketoconazole (200 mg/8 h) followed by 
10 cycles of docetaxel (75 mg/m2 every 3 weeks). Following 
disease progression, the patient received 6 doses of Ra-223 
(50 kBq/kg; 1 dose/4 weeks). During this treatment period, 
an improvement in the patient's symptoms, and levels of bone 
alkaline phosphatase (BAP) and PSA were noted. Further-
more, Ra-223 was well-tolerated without any relevant bone 
marrow toxicity. However, 2 months after the administration 
of the final dose of Ra-223, PSA and BAP levels increased 
again, and bone pain deteriorated. A bone scan showed 
stable disease in the previously observed metastatic lesions; 
however, new lesions simultaneously appeared in different 
locations, indicating progressive disease.
Introduction
Bone metastasis is common in prostate cancer, and the 
majority of patients with castration-resistant prostate cancer 
(CRPC) present with radiographic evidence of bone disease 
and associated symptoms. Up to 80% of patients develop asso-
ciated symptoms of bone disease, including bone pain, bone 
fractures or even spinal cord compression. As prostate cancer 
has a particular propensity to spread to the bone, common 
symptoms include skeletal‑related events (SREs), such as 
pain, fractures, hypercalcemia and medullar compression, 
which result in significant morbidity, worsen patient quality 
of life and comprise the most frequent cause of mortality in 
these patients. Palliative treatment for bone pain associated 
with metastasis includes non-steroidal analgesics and opiates, 
surgery, bone-targeted therapies (bisphosphonates and deno-
sumab) and external beam radiotherapy. The effect of the 
aforementioned treatments are limited to delaying the onset 
of SREs (1,2).
Bone‑targeting radiopharmaceuticals have also been added 
to the treatment options available, as they have been shown 
to be efficient in relieving metastatic bone pain, particularly 
in patients with widespread bone disease (3). The radiophar-
maceuticals most frequently used for bone pain relief are 
β-emitting isotopes, such as 89Sr-chloride, 153Sm-ethylenedi-
aminetetramethylene phosphonic acid and 186Re-etidronate.
Recently, an α-emitting isotope, 223Radium-dichloride 
(Ra-223), has been approved for the treatment of patients with 
CRPC that develop painful bone metastasis without evidence 
of visceral metastases. In general, α-emitters are associated 
with a shorter range (<0.1 mm) and a higher energetic radiation 
compared with β-particles and γ-rays, which have a low Linear 
Energy Transfer (LET) radiation. In addition, α-emitters 
exhibit a tissue penetration diameter of 2‑10 cells, minimizing 
the damage to healthy hematopoietic tissue. Furthermore, due 
to their high LET radiation, α-particles are considered more 
lethal, inducing non‑repairable double‑stranded DNA breaks 
in adjacent tumor cells (4).
Ra-223 is the only radiopharmaceutical that has been 
demonstrated to increase overall survival (OS) in patients with 
CRPC with bone metastasis in a phase III study. The afore-
mentioned study, the ALSYMPCA trial, is an international, 
randomized, double‑blinded, placebo‑controlled study that was 
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conducted in men with symptomatic metastatic CRPC (5). The 
inclusion criteria were symptomatic CRPC, no known visceral 
metastasis, ≥2 bone metastases, and either docetaxel-pretreated 
patients, patients that were unfit for docetaxel treatment 
or patients that refused to receive chemotherapy. Patients 
were randomized in a 2:1 ratio to receive Ra-223 injections 
at 50 kBq/kg plus best standard of care or placebo plus best 
standard of care. Best standard of care included secondary 
hormonal therapies (second- or third-line hormonal maneuvers, 
including, but not limited to, high-dose bicalutamide, predni-
sone and estrogens) or external beam radiotherapy, but not 
cytotoxic chemotherapy or radioisotopes. Patients were divided 
into groups according to total bone alkaline phosphatase (BAP) 
levels, bisphosphonate use and prior docetaxel treatment. The 
primary endpoint was OS, while the secondary endpoints were: 
Time to i) first SRE, ii) total BAP progression, iii) total BAP 
response, iv) total BAP normalization and v) prostate‑specific 
antigen (PSA) progression; vi) adverse events; and vii) affected 
quality of life. The trial included 921 male patients (Ra-223, 
n=614; placebo, n=307). All patients enrolled in the study 
received up to 6 intravenous injections of Ra-223 or placebo, 
administered at 4‑week intervals (5).
The trial was terminated following the recommendation 
of an independent committee, due to early evidence of Ra-223 
benefit in OS. Ra‑223 was shown to significantly improve OS in 
patients with CRPC and bone metastases, as compared with the 
placebo group [hazard ratio (HR), 0.70; 95% confidence interval 
(CI), 0.58‑0.83; median OS, 14.9 vs. 11.3 months; P<0.001]. A 
significant beneficial effect was also observed in all patients 
except for patients with an Eastern Cooperative Oncology 
Group Performance Status of ≥2, possibly due to the limited 
number of patients included in the study. Time to first SRE was 
also found to be significantly prolonged in the in the Ra‑223 
group compared with the placebo group (HR, 0.66; 95% CI, 
0.52‑0.83; median time to first SRE, 15.6 vs. 9.8 months; 
P<0.001) (6). In addition, the quality of life of the patients was 
markedly improved following treatment with Ra‑223 (5‑7), 
with no differences in severe side-effects (grades 3-4) observed 
between the Ra-223 and placebo groups (8).
The findings on the aforementioned studies indicate that 
Ra‑223 should not merely be used to visualize bones, but also 
as a systemic treatment strategy for patients with CRPC devel-
oping bone metastasis, either as first‑line or salvage therapy. 
Ra-223 had a significant benefit on survival, delaying the 
onset of SREs with an acceptable safety profile. This effect 
had not been previously recorded for other available radio-
pharmaceuticals (4). The use of Ra-223 has been approved 
for CRPC patients exhibiting symptomatic bone metastasis 
without visceral disease, regardless of previous treatment with 
docetaxel. In fact, the ALSYMPCA study demonstrated a 
benefit of Ra‑223 on OS compared with the placebo, regardless 
of prior docetaxel treatment (hazard ratio, 0.71 vs. 0.74) (8‑10).
The present study reports the case of a patient with CRPC 
who met the inclusion criteria of the ALPSYMCA trial and 
was treated with Ra-223.
Case report
A 70-year-old male patient, with no history of concomi-
tant diseases, was diagnosed with T3 Gleason 7 (11) 
prostate cancer by echography and transrectal biopsy in 
November 1999 at Hospital Santa Creu I Sant Pau (Barce-
lona, Spain). At that time, the patient had PSA levels of 
12.5 ng/ml (normal range, <4 ng/ml) and a diagnosis of 
clinical stage cT2aNx disease (12). Therefore, a successful 
radical prostatectomy was performed in January 2000. The 
histopathology report of formalin‑fixed sections revealed 
Gleason grade 7 left lobe adenocarcinoma with extrapros-
tatic invasion, non-affected surgical margins and negative 
lymphatic nodes (pT3pN0).
Following definitive pathological staging, a bone scan 
was performed in March 2001, which showed a total of 
2 osteoblastic bone metastases in both ischiopubic branches. 
Subsequent to the diagnosis of metastatic prostate cancer, 
treatment with luteinizing hormone‑releasing hormone 
(LH-RH) analogues was initiated in March 2001. The patient 
achieved a complete biochemical response (PSA level, 
1.03 ng/ml). Hormonal therapy was terminated in May 2004 
due to stable disease, according to Prostate Cancer Working 
Group (PCWG)-2 criteria (13), with undetectable PSA levels 
and a lack of symptoms, within an intermittent therapy 
strategy.
In May 2005, the patient presented with a biochemical 
relapse (PSA level, 77.0 ng/ml) and underwent complete 
androgen blockade (CAB) with bicalutamide (50 mg) 
plus LH-RH analogues, such as gosrelin acetate, until 
November 2006, when treatment was terminated due to unde-
tectable PSA levels.
In December 2007, PSA levels increased again (PSA level, 
105 ng/ml). As a result, CAB was re‑initiated and continued 
until October 2010, as the patient developed progressive disease 
(PD), according to the PCWG‑2 criteria. The patient presented 
with bone pain, therefore, a bone scan was performed. The 
scan showed an increase in the number and extension of 
pelvic metastases compared with the bone scan performed in 
March 2001. 
Between September and October 2010, PSA levels 
increased from 66.8 to 75.6 ng/ml, and BAP levels reached 
594 U/l (normal range, 44-147 U/l). In November 2010, treat-
ment with ketoconazole (200 mg/8 h) was administered until 
July 2011, when PSA increased to 408 ng/ml. A new bone scan 
showed PD with painful pelvic lesions.
In July 2011, following the recurrence of PD, 10 cycles 
of docetaxel (75 mg/m2 every 3 weeks) were administered 
between August 2011 and April 2012, with a good clinical 
and biochemical response (PSA and BAP decreased to 
4.01 ng/ml and 75 U/l, respectively). However, 3 months 
later, PSA and BAP increased to 29.1 ng/ml and 203 U/l, 
respectively, and a bone scan observed progression of bone 
metastasis (new PD). Docetaxel rechallenge (75 mg/m2 
every 3 weeks) was initiated in July 2012; although a clinical 
response initially occurred, the patient developed bone pain 
with radiological progression following the fourth cycle. 
The patient also exhibited biochemical progression (PSA, 
317 ng/ml; BAP, 402 U/l). As the patient had painful PD 
without visceral metastases, treatment with Ra-223 was 
scheduled. A bone scan performed in February 2013 
showed widespread bone metastases on the bilateral ribs, 
dorsolumbar vertebrae, pelvis, sacrum and proximal femurs 
(Fig. 1).
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Between March and August 2013, the patient was treated 
with 6 doses of Ra‑223 (50 kBq/kg; 1 dose/4 weeks). The 
administered doses were: 2.92 MBq (March 12), 3.64 MBq 
(April 8), 3.4 MBq (May 8), 3.3 MBq (June 6), 3.4 MBq 
(July 8) and 3.4 MBq (August 5). During this period, PSA and 
BAP decreased from 317 to 80.1 ng/ml and from 402 to 81 U/l, 
respectively, and bone pain was controlled. Furthermore, 
Ra-223 was well-tolerated without associated bone marrow 
toxicity. However, 2 months after administration of the final 
dose of Ra‑223, PSA and BAP increased to 314.8 ng/ml and 
159 U/l, respectively, and bone pain worsened. A bone scan 
performed in October 2013 did not show any tracer uptake in 
the previously observed metastatic lesions; however, PD was 
evident due to the detection of tracer uptake by new lesions in 
the backbone and head (Fig. 2).
In November 2013, 4 cycles of cabazitaxel (20 mg/m2 
every 3 weeks) were administered. A bone scan performed in 
March 2014 revealed metastatic disease progression (Fig. 3). 
Figure 1. Bone scan performed in February 2013 (prior to 223Ra-dichloride treatment) showing widespread bone metastases on the bilateral ribs, dorsolumbar 
vertebrae, pelvis, sacrum and proximal femurs.
Figure 2. Bone scan performed in October 2013 (2 months after 223Ra‑dichloride treatment) showing new lesions in sites with no previous uptake (arrows).
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Changes in the patient's PSA and BAP levels over time are 
shown in Fig. 4, indicating that the patient is currently 
in clinical and biochemical progression. The patient was 
re‑evaluated every 9 weeks with measurement of PSA levels. 
The final follow‑up was performed in March 2015, and due 
to symptomatic deterioration, the patient was treated only 
for palliative relief subsequent to that date. Written informed 
consent was obtained from the patient and their family for 
publication of the present study.
Discussion
Ra-223 is a bone-targeting calcium mimetic α‑emitter known 
to accumulate in areas of increased bone turnover (4-6). It has 
been reported that α radiation has high LET that generates 
double‑stranded DNA breaks, resulting in elevated cytotoxicity 
and greater biological effectiveness compared with β radia-
tion (7). At present, clinical experience of Ra-223 is limited 
compared with β‑emitting radiopharmaceuticals, with knowl-
edge of Ra‑223 limited to findings from two phase I, three 
phase II and one phase III clinical studies (4). Furthermore, 
in contrast to previous studies based on β-emitter radio-
pharmaceuticals, clinical studies assessing the effectiveness 
of Ra-223 in relieving bone pain used primary endpoints of 
OS and secondary endpoints of time to the first symptomatic 
skeletal‑related event (9).
The dosage of Ra-223 depends on body weight and, due 
to its higher biological effectiveness; administered doses are 
Figure 3. Bone scan performed in March 2014 showing metastatic disease progression, with new bone metastases in the backbone and head.
Figure 4. Changes in BAP and PSA levels over time. The two squares indicate the time and response when the patient was treated with docetaxel and 
223Ra‑dichloride, respectively. BAP, bone alkaline phosphatase; PSA, prostate‑specific antigen.
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smaller than those applicable to β-emitting radiopharma-
ceuticals. A large multicentric double‑blinded randomized 
phase III clinical study showed that 6 doses of 50 kBq/kg 
administered once every 4 weeks resulted in a significant 
decrease in bone marker levels and a significant delay in the 
onset of SREs, resulting in improved OS and pain relief (6). 
Additional clinical studies compared different dosages of 
Ra-223 or compared Ra-223 with a placebo and achieved 
similar results (4-6,14-18).
In the present case, a patient with CRPC treated with 
6 intravenous doses of Ra‑223 (50 kBq/kg) achieved bone pain 
relief, and a significant decrease in PSA and BAP levels. In 
addition, 2 months after the administration of the final dose, 
a bone scan showed improvement of the widespread bone 
metastases, with tracer uptake normalization in the metastatic 
lesions of the ribs and pelvis. PSA response is unusual under 
Ra‑223 treatment, whereas BAP response is common. There-
fore, it has been recommended that changes in BAP should be 
considered as a biomarker of response to Ra‑223 treatment; 
however, this only applies to patients with elevated BAP levels 
at baseline. In the present patient, PD was indicated by the 
appearance of new metastatic lesions located in sites where 
no Ra‑223 uptake had previously been reported. Notably, a 
response to β-emitting isotopes is not commonly observed 
upon imaging, however, partial responses may be observed 
with Ra-223. In the present patient, pain relief was achieved, 
with normalization of tracer uptake in the bone metastases 
that were previously present, and a decrease in BAP and PSA 
levels during Ra-223 treatment.
Evaluating drugs for the treatment of prostate cancer 
poses certain challenges. For example, measurable disease 
occurs infrequently. As a result, the PCWG addressed this 
and various other challenges in their consensus recommenda-
tions for the conduct of clinical trials. Although the Response 
Evaluation Criteria in Solid Tumors (RECIST) are consider-
ably well-established recommendations, they do not consider 
certain key characteristics of prostate cancer; for example, 
post-therapeutic changes in PSA levels were not addressed by 
RECIST (19).
Despite the developments made in imaging modalities, 
interpreting the clinical significance of changes in the size or 
intensity of bone metastases observed on bone scans is chal-
lenging. In cases where a bone scan is the sole indicator of 
progression, PCWG defines bone disease progression as the 
appearance of ≥2 new lesions on a bone scan compared with a 
prior scan for trial entry. When scan findings are suggestive of 
the appearance of new lesions or a flare reaction, possibly due 
to trauma, it may prove useful to confirm these results using 
other imaging modalities (13).
In addition, it should be taken into consideration that the 
findings of scans can potentially appear worse before they 
improve, resulting in the erroneous conclusion that the treat-
ment has failed when, in fact, it was too early to assess the 
effect of the drug (20).
In conclusion, in the present study a patient with CRPC 
was treated with Ra-223 without major toxicities. Following 
the development of PD, the patient was treated with cabazi-
taxel. The results of ongoing randomized trials are required 
to determine whether Ra-223 or docetaxel rechallenge can be 
part of a long-term treatment regime.
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